(Q36070934)

12 August 2017

1 reference

title

Thiazolidinediones for treatment of polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

12 August 2017

1 reference

1 reference

Dena L Stout

1

1 reference

PubMed ID

15767238

12 August 2017

Susan E Fugate

series ordinal

2

1 reference

PubMed ID

15767238

12 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

12 August 2017

1 reference

12 August 2017

25

1 reference

12 August 2017

2

1 reference

12 August 2017

244-252

1 reference

Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study

12 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Polycystic ovary syndrome: clinical perspectives and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Assessment and management of anovulatory infertility in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Insulin sensitizers for polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

The pathophysiology of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

New approach to polycystic ovary syndrome and other forms of anovulatory infertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Pharmacologic Treatment of Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

Differentiating members of the thiazolidinedione class: a focus on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.2.244.56943

10.1592/PHCO.25.2.244.56943

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15767238